

Figure S1. Statistical analysis of western blotting and IHC results. (A) PGBD5 protein expression in five cases of glioma tissues and adjacent non-cancerous tissues. (B) PGBD5 protein expression in NHAs and glioma cell lines (A172, U251 and U87). (C) PGBD5 protein expression in sh-PGBD5 and sh-NC groups in glioma cell lines (A172, U251 and U87). Expression of apoptosis-related proteins (D) Bax, (E) Bcl-2, (F) cleaved caspase-3 (17 kDa) and (G) cleaved-caspase 3 (19 kDa) in glioma cell lines after PGBD5 knockdown. Expression of cell cycle-related proteins (H) CDK1 and (I) cyclin B1 in glioma cell lines after PGBD5 knockdown. (J) PPAR δ protein expression in glioma cell lines after PGBD5 knockdown. (K) p-PPAR δ (Thr 256), (L) PPAR γ and (M) p-PPAR γ (Ser 273) protein expression in glioma cell lines after PGBD5 knockdown. (N) Differential expression of Ki67 within tumor samples after PGBD5 knockdown, as detected using IHC. (O) PPAR γ and (P) PPAR δ levels in in vivo subcutaneous tumors after PGBD5 knockdown. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. NC, negative control; NHA, normal human astrocyte; p-, phosphorylated; PGBD5, piggyBac transportable element derived 5; PPAR, peroxisome proliferator-activated receptor; sh, short hairpin; IHC, immunohistochemistry.

